Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.

Kadota K, Suzuki K, Sima CS, Rusch VW, Adusumilli PS, Travis WD.

J Thorac Oncol. 2011 May;6(5):896-904. doi: 10.1097/JTO.0b013e318211127a.

2.

High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.

Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Adusumilli PS.

J Thorac Oncol. 2012 Jul;7(7):1192-7. doi: 10.1097/JTO.0b013e3182519d96.

3.

Reproducibility of histological subtyping of malignant pleural mesothelioma.

Brčić L, Jakopović M, Brčić I, Klarić V, Milošević M, Sepac A, Samaržija M, Seiwerth S.

Virchows Arch. 2014 Dec;465(6):679-85. doi: 10.1007/s00428-014-1664-9. Epub 2014 Oct 10.

PMID:
25300229
4.

A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Kadota K, Suzuki K, Colovos C, Sima CS, Rusch VW, Travis WD, Adusumilli PS.

Mod Pathol. 2012 Feb;25(2):260-71. doi: 10.1038/modpathol.2011.146. Epub 2011 Oct 7.

5.

Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.

Kadota K, Villena-Vargas J, Nitadori J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Ann Surg Oncol. 2015 Sep;22(9):3136-43. doi: 10.1245/s10434-015-4374-x. Epub 2015 Jan 22.

6.

Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.

Alchami FS, Attanoos RL, Bamber AR.

J Clin Pathol. 2017 Feb;70(2):179-182. doi: 10.1136/jclinpath-2016-203993. Epub 2016 Oct 18.

PMID:
27798081
7.

Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?

Balduyck B, Trousse D, Nakas A, Martin-Ucar AE, Edwards J, Waller DA.

Ann Thorac Surg. 2010 Mar;89(3):907-11. doi: 10.1016/j.athoracsur.2009.12.041.

PMID:
20172152
8.

Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.

Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D'Amico TA, Harpole DH, Berry MF.

J Surg Res. 2015 Jun 1;196(1):23-32. doi: 10.1016/j.jss.2015.01.043. Epub 2015 Jan 29.

9.

Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.

Gill RR, Umeoka S, Mamata H, Tilleman TR, Stanwell P, Woodhams R, Padera RF, Sugarbaker DJ, Hatabu H.

AJR Am J Roentgenol. 2010 Aug;195(2):W125-30. doi: 10.2214/AJR.09.3519.

PMID:
20651171
10.

Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.

Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, Travis WD, Adusumilli PS.

Cancer Immunol Immunother. 2011 Dec;60(12):1721-8. doi: 10.1007/s00262-011-1073-8. Epub 2011 Jul 19.

PMID:
21769693
11.

Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.

Johansson L, Lindén CJ.

Chest. 1996 Jan;109(1):109-14.

PMID:
8549169
12.

Pathohistological diagnosis and differential diagnosis.

Tischoff I, Neid M, Neumann V, Tannapfel A.

Recent Results Cancer Res. 2011;189:57-78. doi: 10.1007/978-3-642-10862-4_5. Review.

PMID:
21479896
13.

The recurrence of malignant pleural mesothelioma 14 years after extrapleural pneumonectomy: possible histological transformation.

Kinoshita T, Ishii G, Matsumura Y, Shiozawa T, Aokage K, Hishida T, Yoshida J, Nagai K.

Pathol Int. 2012 Nov;62(11):754-7. doi: 10.1111/pin.12003.

PMID:
23121607
14.

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.

15.

Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales.

Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N.

Br J Cancer. 2014 Oct 28;111(9):1860-9. doi: 10.1038/bjc.2014.478. Epub 2014 Sep 4.

16.

The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.

Galateau-Salle F, Churg A, Roggli V, Travis WD; World Health Organization Committee for Tumors of the Pleura..

J Thorac Oncol. 2016 Feb;11(2):142-54. doi: 10.1016/j.jtho.2015.11.005. Review.

17.

Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.

Krasinskas AM, Borczuk AC, Hartman DJ, Chabot JA, Taub RN, Mogal A, Pingpank J, Bartlett D, Dacic S.

Histopathology. 2016 Apr;68(5):729-37. doi: 10.1111/his.12807. Epub 2015 Oct 16.

PMID:
26272336
18.

Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis.

Mogi A, Nabeshima K, Hamasaki M, Uesugi N, Tamura K, Iwasaki A, Shirakusa T, Iwasaki H.

Pathol Int. 2009 Dec;59(12):874-9. doi: 10.1111/j.1440-1827.2009.02459.x.

PMID:
20021613
19.

Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.

Nind NR, Attanoos RL, Gibbs AR.

Histopathology. 2003 Feb;42(2):150-5.

PMID:
12558747
20.

Clinical significance of the expression of tumor-associated antigen, RCAS1, and its soluble protein in pleural fluid in malignant mesothelioma.

Hiraki A, Aoe K, Murakami T, Nakamura Y, Yamazaki K, Sueoka N, Taguchi K, Kamei T, Maeda T, Takeyama H, Kishimoto T, Nishimura M, Sugi K.

Oncol Rep. 2005 Aug;14(2):357-62.

PMID:
16012715

Supplemental Content

Support Center